| 1 |
Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T-ALL like mutations. ( 30117174
)
|
Mi X...Weinberg OK
|
2018 |
| 2 |
NOTCH1 pathway activating mutations and clonal evolution in pediatric T-cell acute lymphoblastic leukemia (T-ALL). ( 30387229
)
|
Kimura S...Takita J
|
2018 |
| 3 |
T-ALL leukemia stem cell 'stemness' is epigenetically controlled by the master regulator SPI1. ( 30412053
)
|
Zhu H...Wu H
|
2018 |
| 4 |
T cell acute lymphoblastic leukemia (T-ALL): New insights into the cellular origins and infiltration mechanisms common and unique among hematologic malignancies. ( 28830639
)
|
Vadillo E...Schnoor M
|
2018 |
| 5 |
Matrine induced G0/G1 arrest and apoptosis in human acute T-cell lymphoblastic leukemia (T-ALL) cells. ( 29045804
)
|
Tetik Vardarl? A...?etintas VB
|
2018 |
| 6 |
IGF1 Brings Growing Pains for T-ALL LSCs. ( 30388418
)
|
Mullighan CG
|
2018 |
| 7 |
Correlation of expression of aberrant immunophenotypic markers in T-ALL with its morphology: A pilot study. ( 30498313
)
|
Garg N...Sikka M
|
2018 |
| 8 |
Co-targeting intracellular pH and essential amino acid uptake cooperates to induce cell death of T-ALL/LL cells. ( 28641473
)
|
Imbert V...Peyron JF
|
2018 |
| 9 |
Drugging DNA repair to target T-ALL cells. ( 29115896
)
|
Dasgupta Y...Skorski T
|
2018 |
| 10 |
Defining the molecular basis of oncogenic cooperation between TAL1 expression and Pten deletion in T-ALL using a novel pro-T-cell model system. ( 29151585
)
|
Bornschein S...de Bock CE
|
2018 |
| 11 |
Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL. ( 29187379
)
|
Degryse S...Cools J
|
2018 |
| 12 |
Case report: Exome sequencing identifies T-ALL with myeloid features as a IKZF1-struck early precursor T-cell malignancy. ( 29204341
)
|
Hansen MC...Hokland P
|
2018 |
| 13 |
MBD2 Ablation Impairs Lymphopoiesis and Impedes Progression and Maintenance of T-ALL. ( 29330145
)
|
Zhou M...Zhou J
|
2018 |
| 14 |
Novel Intergenically Spliced Chimera, NFATC3-PLA2G15, Is Associated with Aggressive T-ALL Biology and Outcome. ( 29330284
)
|
Bond J...Asnafi V
|
2018 |
| 15 |
Refining genetic stratification in T-ALL. ( 29348308
)
|
O'Connor D
|
2018 |
| 16 |
MIR-708 promotes phagocytosis to eradicate T-ALL cells by targeting CD47. ( 29368647
)
|
Huang W...Chen YQ
|
2018 |
| 17 |
Characterization of Camptothecin-induced Genomic Changes in the Camptothecin-resistant T-ALL-derived Cell Line CPT-K5. ( 29496689
)
|
Kjeldsen E...Knudsen BR
|
2018 |
| 18 |
"Dar"-ing to target CD38 in T-ALL. ( 29496700
)
|
Wynne J...Stock W
|
2018 |
| 19 |
AKR1C enzymes sustain therapy resistance in paediatric T-ALL. ( 29515258
)
|
Bortolozzi R...Persano L
|
2018 |
| 20 |
Saracatinib impairs maintenance of human T-ALL by targeting the LCK tyrosine kinase in cells displaying high level of lipid rafts. ( 29535432
)
|
Buffi?re A...Qu?r? R
|
2018 |
| 21 |
Investigation of BAX and BCL2 expression and apoptosis in a resveratrol- and prednisolone-treated human T-ALL cell line, CCRF-CEM. ( 29662863
)
|
Khanzadeh T...Baradaran B
|
2018 |
| 22 |
Aberrant activity of NKL homeobox gene NKX3-2 in a T-ALL subset. ( 29746601
)
|
Nagel S...Drexler HG
|
2018 |
| 23 |
High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-ALL. ( 29746793
)
|
Perez DR...Matlawska-Wasowska K
|
2018 |
| 24 |
The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL. ( 29930300
)
|
Kampen KR...De Keersmaecker K
|
2018 |
| 25 |
Expression of CD56 defines a distinct subgroup in childhood T-ALL with inferior outcome. Results of the ALL-BFM 2000 trial. ( 30028023
)
|
Fuhrmann S...Ratei R
|
2018 |
| 26 |
Selective killing of human T-ALL cells: an integrated approach targeting redox homeostasis and the OMA1/OPA1 axis. ( 30069011
)
|
Silic-Benussi M...Ciminale V
|
2018 |
| 27 |
NOTCH1 Signaling Hijacks the Stress Response to Promote T-ALL. ( 30076148
)
|
|
2018 |
| 28 |
Apoptotic effect of resveratrol on human T-ALL cell line CCRF-CEM is unlikely exerted through alteration of BAX and BCL2 promoter methylation. ( 30132966
)
|
Zadi Heydarabad M...Farshdousti Hagh M
|
2018 |
| 29 |
Dysregulated transcriptional networks in KMT2A- and MLLT10-rearranged T-ALL. ( 30159143
)
|
Kang H...Matlawska-Wasowska K
|
2018 |
| 30 |
NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263. ( 30224339
)
|
Dastur A...Benes CH
|
2018 |
| 31 |
MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells. ( 30297804
)
|
Huang XB...Qian WB
|
2018 |
| 32 |
Successful second allogeneic stem cell transplantation in a patient with T-lymphoblastic leukemia (T-ALL) relapsed as myeloid sarcoma. ( 28451803
)
|
Matern S...Stelljes M
|
2017 |
| 33 |
DNMT3B overexpression contributes to aberrant DNA methylation and MYC-driven tumor maintenance in T-ALL and Burkitt's lymphoma. ( 29100357
)
|
Poole CJ...van Riggelen J
|
2017 |
| 34 |
The effect of the JAK2 inhibitor TG101209 against T cell acute lymphoblastic leukemia (T-ALL) is mediated by inhibition of JAK-STAT signaling and activation of the crosstalk between apoptosis and autophagy signaling. ( 29290986
)
|
Cheng Z...Zhang G
|
2017 |
| 35 |
CARMA1 is a novel regulator of T-ALL disease and leukemic cell migration to the CNS. ( 27698445
)
|
Oruganti SR...Cannon JL
|
2017 |
| 36 |
T-ALL: several homes rather than homeless? ( 27824040
)
|
Rak J...M?ndez-Ferrer S
|
2017 |
| 37 |
The genetics and molecular biology of T-ALL. ( 28115373
)
|
Girardi T...De Keersmaecker K
|
2017 |
| 38 |
Synergistic antileukemic therapies in NOTCH1-induced T-ALL. ( 28174276
)
|
Sanchez-Martin M...Ferrando AA
|
2017 |
| 39 |
Targeted therapies for T-cell acute lymphoblastic leukaemia (T-ALL): what makes T-ALL TYK? ( 28211568
)
|
Curtis DJ
|
2017 |
| 40 |
Regarding the sudden death of a juvenile with rare TdT-negative T-LBL/T-ALL, splenic rupture, and mediastinal mass. ( 28215035
)
|
Nikoli? S...?ivkovi? V
|
2017 |
| 41 |
Dnmt3a regulates T-cell development and suppresses T-ALL transformation. ( 28321121
)
|
Kramer AC...Challen GA
|
2017 |
| 42 |
Response to "regarding the sudden death of a juvenile with rare TdT-negative T-LBL/T-ALL, splenic rupture, and mediastinal mass". ( 28405884
)
|
Gascho D...Bolliger SA
|
2017 |
| 43 |
A TCR-switchable cell death pathway in T-ALL. ( 28540327
)
|
Quang CT...Ghysdael J
|
2017 |
| 44 |
MRD response in a refractory paediatric T-ALL patient through anti-programmed cell death 1 (PD-1) Ab treatment associated with induction of fatal GvHD. ( 28581460
)
|
Boekstegers AM...Feuchtinger T
|
2017 |
| 45 |
Creation of a human T-ALL cell line online database. ( 28609209
)
|
Squiban B...Frazer JK
|
2017 |
| 46 |
Novel oncogenic noncoding mutations in T-ALL. ( 28620102
)
|
Goossens S...Van Vlierberghe P
|
2017 |
| 47 |
Outcome and Clinical Significance of Immunophenotypic Markers Expressed in Different Treatment Protocols of Pediatric Patients With T-ALL in Developing Countries. ( 28624542
)
|
Sayed DM...Al-Saber A
|
2017 |
| 48 |
Pediatric T-ALL complicated by irreversible nelarabine neurotoxicity. ( 28745456
)
|
Kanayama T...Hosoi H
|
2017 |
| 49 |
In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL. ( 28885610
)
|
Laukkanen S...Lohi O
|
2017 |
| 50 |
Nelarabine toxicity in children and adolescents with relapsed/refractory T-ALL/T-LBL: can we avoid throwing the baby out with the bathwater? ( 28891074
)
|
Malone A...Smith OP
|
2017 |
